Human papillomavirus vaccines

Seminars in Cancer Biology

Volumn 9, Issue 6, 1999, Pages 431-445

  Breitburd, Françoise ^a   Coursaget, Pierre ^b  

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

Animal models; Clinical trials; Early HPV proteins; Prophylactic vaccines; Therapeutic vaccines; Virus like particles

Indexed keywords

ANESTHETIC AGENT; CHOLERA TOXIN; RECOMBINANT VACCINE; STRUCTURAL PROTEIN; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN; VIRUS VACCINE; WART VIRUS VACCINE;

CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL MODEL; GENITAL TRACT TUMOR; HUMAN; IMMUNE RESPONSE; LESIONS AND DEFECTS; NONHUMAN; PAPILLOMA VIRUS; PROPHYLAXIS; REVIEW; SALMONELLA TYPHIMURIUM; SEXUALLY TRANSMITTED DISEASE; TUMOR REGRESSION; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

EID: 0033510659     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1999.0147     Document Type: Article

References (102)

1. Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P. Immunisation against hepatitis B in man. Lancet. 1:1976;1367-1370.
2. Orth G. Papillomaviruses - human (Papovaviridae): general features, Webster R G, Granhoff A,. Encyclopedia of Virology. 1999;1105-1114 Academic Press Ltd., London.
3. Brandsma JL. Animal models for human papillomavirus vaccine development, Lacey C,. Papillomavirus Reviews: Current Research on Papillomaviruses. 1996;69-78 Leeds University Press, Leeds.
4. Breitburd F, Salmon J, Orth G. Animal models for evaluation of human papillomavirus vaccines, Franco E L, Monsonego J,. New Developments in Cervical Cancer Screening and Prevention. 1997;432-445 Blackwell Science Ltd., Oxford
5. Lowy DR, Schiller JT. Papillomaviruses: prophylactic vaccine prospects. Biochim Biophys Acta. 1423:1998.
6. Galloway DA. Is vaccination against human papillomavirus a possibility? Lancet. 351: 1998;22-24.
7. Gariglio P, Benitez-Bribiesca L, Berumen J, Alcocer JM, Tamez R, Madrid V. Therapeutic uterine-cervix cancer vaccines in humans. Arch Med Res. 29:1998;279-284.
8. Hines JF, Ghim S, Jenson AB. Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Curr Opin Obstet Gynecol. 10:1998;15-19.
9. Coursaget P, Muñoz N. Vaccination against infectious agents associated with human cancer. Cancer Surv. 33:1999;355-381.
10. Murakami M, Gurski KJ, Steller MA. Human papillomavirus vaccines for cervical cancer. J Immunother. 22:1999;212-218.
11. Schiller JT. Papillomavirus-like particle vaccines for cervical cancer. Mol Med Today. 5:1999;209-215.
12. Tindle RW (ed). Vaccines for Human Papillomavirus Infection and Anogenital Disease. 1999;R.G. Lands Company, Austin.
13. van Driel WJ, Kenter GG, Fleuren GJ, Melief CJM, Trimbos BJ. Immunotherapeutic strategies for cervical squamous carcinoma. Hematol Oncol Clin North Am. 13:1999;259-273.
14. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1995;IARC, Lyon
15. Koutsky, L, A
16. Breitburd F, Ramoz N, Salmon J, Orth G. HLA control in the progression of human papillomavirus infections. Semin Cancer Biol. 7:1996;359-371.
17. Melkert PWJ, Hopman E, van den Brule AJC, Risse EKJ, van Diest PJ, Bleker OP, Helmerhorst T, Schipper MEI, Meijer CJLM, Walboomers JMM. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 53:1993;919-923.
18. Bonnez W. Murine models of human papillomavirus-infected human xenografts. Papillomavirus Rep. 9:1998;27-38.
19. Breitburd F, Salmon J, Orth G. The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Clin Dermatol. 15:1997;237-247.
20. Frazer IH, Thomas R, Zhou JA, Leggatt GR, Dunn L, McMillan N, Tindle RW, Filgueira L, Manders P, Barnard P, Sharkey M. Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev. 168:1999;131-142.
21. Schneider-Maunoury S, Croissant O, Orth G. Integration of human papillomavirus type16 DNA sequences: a possible early event in the progression of genital tumors. J Virol. 61:1987;3295-3298.
22. Touzé A, Coursaget P. in vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res. 26:1998;1317-1323.
23. Combita, A, L, Touze, A, Bousarghin, L, El Mehdaoui, S, Sizaret, P, Y, Munoz, N, Coursaget, P, Gene transfer using virus-like particles from seven different human papillomaviruses.
24. Müller M, Zhou JA, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L. Chimeric papillomavirus-like particles. Virology. 234:1997;93-111.
25. De Bruijn MLH, Greenstone HL, Vermeulen H, Melief CJM, Lowy DR, Schiller JT, Kast WM. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology. 250:1998;371-376.
26. Marais D, Passmore J-A, Maclean J, Rose R, Williamson A-L. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. J Gen Virol. 80:1999;2471-2475.
27. Rudolf MP, Nieland JD, Da Silva DM, Velders MP, Muller M, Greenstone HL, Schiller JT, Kast WM. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem. 380:1999;335-340.
28. Kast WM, Feltkamp MCW, Ressing ME, Vierboom MPM, Brandt RMP, Melief CJM. Cellular immunity against human papillomavirus associated cervical cancer. Semin Virol. 7:1996;117-123.
29. Ressing ME, Toes REM, Shoenberger SP, Brandt RMP, de Jong JH, Kast WM, Offringa R, Melief CJM. Anti-tumor immunotherapy with synthetic peptides representing tumor-associated T-cell epitopes: implications for peptide-based vaccination of cervical cancer, Tindle R W,. Vaccines for Human Papillomavirus Infection and Anogenital Disease. 1999;53-68 R.G. Lands Company, Austin.
30. Wettstein FO. State of viral DNA and gene expression in bening vs. malignant tumors, Pfister H,. Papillomaviruses and Human Cancer. 1990;155-179 CRC Press, Boca Raton.
31. Campo MS. Infection by bovine papillomavirus and prospects for vaccination. Trends Microbiol. 3:1995;92-97.
32. Salmon J, Ramoz N, Cassonnet P, Orth G, Breitburd F. A cottontail rabbit papillomavirus strain (CRPVb) with strikingly divergent E6 and E7 oncoproteins: an insight in the evolution of papillomaviruses. Virology. 235:1997;228-234.
33. Ghim SJ, Newsome J, Jenson AB, Schlegel R, Suzich J, Tamura J, White W, Hill F, Warrener P, Bell JA, Sundberg J. Formalin-inactivated oral papilloma extracts and recombinant L1 vaccines protect completely against mucosal papillomavirus infection: a canine model, Chanock R M,. Molecular Approaches to the Control of Infectious Diseases. 1995;375-379 Cold Spring Harbor Laboratory Press, Plainview
34. De Bruijn MLH, Schuurhuis DH, Vierboom MPM, Vermeulen H, de Cock KAJ, Ooms ME, Ressing ME, Toebes M, Franken KLMC, Drijfhout JW, Ottenhoff THM, Offringa R, Melief CJM. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res. 58:1998;724-731.
35. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol. 64:1990;3151-3156.
36. Lin Y-L, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology. 187:1992;612-619.
37. Lin Y-L, Borenstein LA, Ahmed R, Wettstein FO. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J Virol. 67:1993;4154-4162.
38. Donnelly JJ, Martinez D, Jansen KU, Ellis RW, Montgomery DL, Liu MA. Protection against papillomavirus with a polynucleotide vaccine. J Infect Dis. 173:1996;314-320.
39. Sundaram P, Tigelaar RE, Brandsma JL. Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Vaccine. 15:1997;664-671.
40. Chandrachud LM, Grindlay GJ, McGarvie GM, O'Neil BW, Wagner ER, Jarrett WFH, Campo MS. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology. 211:1995;204-208.
41. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G, Schiller JT, Lowy DR. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 69:1995;3959-3963.
42. Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol. 70:1996;960-965.
43. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC, Donnelly JJ, Martinez D, Ellis RW, Shaw AR. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV- induced papilloma formation. Vaccine. 13:1995;1509-1514.
44. Suzich JA, Ghim S-J, Palmer-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenson AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. 92:1995;11553-11557.
45. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A, McGarvie GM, Schiller JT, Lowy DR, Campo MS. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44.
46. Selvakumar R, Borenstein LA, Lin Y-L, Ahmed R, Wettstein FO. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J Virol. 69:1995;602-605.
47. Han R, Reed CA, Cladel NM, Christensen ND. Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces T cell-mediated but not humoral immune responses in rabbits. Vaccine. 17:1999;1558-1566.
48. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol. 71:1997;8467-8474.
49. Lathe R, Kieny MP, Dott K, Gauthier C, Clertant P, Cuzin F, Breitburd F, Orth G, Meneguzzi G. Vaccination against polyoma- and papillomavirus-induced tumors using vaccinia recombinants expressing non-structural proteins, Mehens A, Spier R E,. Vaccines for Sexually Transmitted Diseases. 1989.
50. Meneguzzi G, Cerni C, Kieny MP, Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181:1991;62-69.
51. Sundaram P, Tigelaar RE, Xiao W, Brandsma JL. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine. 16:1998;613-623.
52. McGarvie GM, Grindlay GJ, Chandrachud LM, O'Neil BW, Jarrett WFH, Campo MS. T cell responses to BPV-4 E7 during infection and mapping of T cell epitopes. Virology. 206:1995;504-510.
53. Ressing ME, de Jong JH, Brandt RMP, Drijfhout JW, Benckhuijsen WE, Schreuder GMT, Offringa R, Kast WM, Melief CJM. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 29:1999;1292-1303.
54. Han RC, Cladel NM, Reed CA, Peng XW, Christensen ND. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes. J Virol. 73:1999;7039-7043.
55. Selvakumar R, Ahmed R, Wettstein FO. Tumor regression is associated with a specific immune response to the E2 protein of cottontail rabbit papillomavirus. Virology. 208:1995;298-302.
56. Greenstone HL, Nieland JD, de Visser KE, De Bruijn MLH, Kirnbauer R, Roden RBS, Lowy DR, Kast WM, Schiller JT. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA. 95:1998;1800-1805.
57. Peng SW, Frazer IH, Fernando GJ, Zhou J. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology. 240:1998;147-157.
58. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Muller M, Kast WM. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem. 73:1999;145-152.
59. Schäfer K, Muller M, Faath S, Henn A, Osen W, Zentgraf H, Benner A, Gissmann L, Jochmus I. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection. Int J Cancer. 81:1999;881-888.
60. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, Leo O. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer. 81:1999;428-437.
61. Roden RBS, Hubbert NL, Kirnbauer R, Breitburd F, Lowy DR, Schiller JT. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J Virol. 69:1995;5147-5151.
62. Tan J, Yang NS, Turner JG, Niu GL, Maassab HF, Sun J, Herlocher ML, Chang AE, Yu H. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther. 6:1999;331-339.
63. Fernando GJP, Stewart TJ, Tindle RW, Frazer IH. Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short-term whereas pre-existing Th2 responses are dominant in the longer term. Scand J Immunol. 47:1998;459-465.
64. Schiller JT, Roden RBS. Papillomavirus-like particles. Papillomavirus Rep. 6:1995;121-128.
65. Kawana K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6. J Virol. 73:1999;6188-6190.
66. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. in vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol. 72:1998;959-964.
67. Christensen ND, Kirnbauer R, Schiller JT, Ghim SJ, Schlegel R, Jenson AB, Kreider JW. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 205:1994;329-335.
68. Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type-1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol. 67:1993;315-322.
69. Kirnbauer R, Taub J, Greenstone H, Roden R, Dürst M, Gissmann L, Lowy DR, Schiller JT. Efficient self-assembly of human papillomavirus type-16 L1 and L1-L2 into virus-like particles. J Virol. 67:1993;6929-6936.
70. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991;251-257.
71. Nardelli-Haefliger D, Roden RBS, Benyacoub J, Sahli R, Kraehenbuhl JP, Schiller JT, Lachat P, Potts A, De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun. 65:1997;3328-3336.
72. Benyacoub J, Hopkins S, Potts A, Kelly S, Kraehenbuhl JP, Curtiss R, DeGrandi P, Nardelli-Haefliger D. The nature of the attenuation of Salmonella typhimurium strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. Infec Immun. 67:1999;3674-3679.
73. Unckell F, Streeck RE, Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol. 71:1997;2934-2939.
74. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV, The International Biological Study on Cervical Cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst. 87:1995;796-802.
75. Hagensee ME, Carter JJ, Wipf GC, Galloway DA. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology. 206:1995;174-182.
76. Dupuy C, Buzoni-Gatel D, Touzé A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol. 73:1999;9063-9071.
77. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagin. Infect Immun. 65:1997;2676-2684.
78. Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine. 17:1999;2129-2135.
79. Roden RBS, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT. in vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol. 70:1996;5875-5883.
80. Smith LH, Foster C, Hitchcock ME, Leiserowitz GS, Hall K, Isseroff R, Christensen ND, Kreider JW. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J Invest Dermatol. 105:1995;438-444.
81. Rose RC, White WI, Li ML, Suzich JA, Lane C, Garcea RL. Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol. 72:1998;6151-6154.
82. Cheng G, Icenogle JP, Kirnbauer R, Hubbert NL, StLouis ME, Han CL, Svare EI, Kjaer SK, Lowy DR, Schiller JT. Divergent human papillomavirus type 16 variants are serologically cross-reactive. J Infect Dis. 172:1995;1584-1587.
83. Touzé A, ElMehdaoui S, Sizaret PY, Mougin C, Muñoz N, Coursaget P. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol. 36:1998;2046-2051.
84. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst. 86:1994;494-499.
85. van Driel WJ, Ressing ME, Kenter GG, Brandt RMP, Krul EJT, van Rossum AB, Schuuring E, Offringa R, Bauknecht T, Tamm-Hermelink A, van Dam PA, Fleuren GJ, Kast WM, Melief CJM, Trimbos JB. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer. 35:1999;946-952.
86. Boursnell MEG, Rutherford E, Hickling JK, Rollinson EA, Munro AJ, Rolley N, McLean CS, Borysiewicz LK, Vousden K, Inglis SC. Construction and characterisation of a recombinant vaccinia was expressing human papillomavirus proteins for immunotherapy of cervical cancer. Vaccine. 14:1996;1485-1494.
87. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GWG, Westmoreland D, Evans AS, Adams M, Stacey SN, Boursnell MEG, Rutherford E, Hickling JK, Inglis SC. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
88. Krul MRL, Tijhaar EJ, Kleijne JAFW, Van Loon AM, Nievers MG, Schipper H, Geerse L, Van der Kolk M, Steerenberg PA, Mooi FR, Den Otter W. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization with HPV recombinant Salmonella strains. Cancer Immunol Immunother. 43:1996;44-48.
89. Murakami M, Gurski KJ, Marincola FM, Ackland J, Steller MA. Induction of specific CD8+ T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells. Cancer Res. 59:1999;1184-1187.
90. +lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16-and 18-positive cervical cancer. J Virol. 73:1999;5402-5410.
91. Stevenson SL, Wu TC. Experimental vaccine strategies for cancer immunotherapy, Tindle R W,. Vaccines for Human Papillomavirus Infection and Anogenital Disease. 1999;149-172 R.G. Lands Company, Austin.
92. Lin K-Y, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu T-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
93. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 4:1998;2103-2109.
94. Shi W, Bu P, Liu JZ, Polack A, Fisher S, Qiao L. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity. J Virol. 73:1999;7877-7881.
95. Frazer IH, Tindle RW, Fernando GJP, Malcolm K, Herd K, McFadyn S, Cooper PD, Ward B. Safety and immunogenicity of HPV16 E7/algammulin, Tindle R W. Vaccines for Human Papillomavirus Infection and Anogenital Disease. 1999;91-104 R.G. Lands Company, Austin.
96. Hong K, Greer CE, Ketter N, Van Nest G, Paliard X. Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts. J Virol. 71:1997;6427-6432.
97. McNeil C. HPV vaccines for cervical cancer move toward clinic, encounter social issues. J Natl Cancer Inst. 89:1997;1664-1666.
98. McNeil C. HPV vaccine treatment trials proliferate, diversify. J Natl Cancer Inst. 89:1997;280-281.
99. Jochmus I, Schäfer K, Faath S, Müller M, Gissmann L. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res. 30:1999;269-274.
100. Thompson HSG, Davies ML, Holding FP, Fallon RE, Mann AE, O'Neill T, Roberts JSC. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine. 17:1999;40-49.
101. Lacey CJN, Thompson HSG, Monteiro EF, O'Neill T, Davies ML, Holding FP, Fallon RE, Roberts JSC. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis. 179:1999;612-618.
102. St. Clair Roberts J, Neill T, Lacey C, Rowen D, Sterling J, Monteiro E, Clark L, Thompson S. Vaccine for genital warts, Tindle R W,. Vaccines for Human Papillomavirus Infection and Anogenital Disease. 1999;39-52 R.G. Lands Company, Austin.